The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview
Autor(a) principal: | |
---|---|
Data de Publicação: | 1993 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Memórias do Instituto Oswaldo Cruz |
Texto Completo: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761993000200024 |
Resumo: | Recently, we proposed the hypothesis according to wich the central hypotensive effect of clonidine and related substances could be related to an action upon specific receptors, requiring the imidazoline or imidazoline-like structures, rather than alpha2-adrenoceptors. Since then, direct evidences have been accumulated to confirm the existence of a population of imidazoline specific binding sites in the brainstem of animals and man, more precisely in the Nucleus Reticularis Lateralis (NRL) region of the ventrolateral medulla (VLM), site of the antihypertensive action of clonidine. The purification of the putative endogenous ligand of the imidazoline receptors - named endazoline - is currently being attempted from human brain extracts. This new concept might at last lead to the expected dissociation of the pharmacological mechanisms involved, on the one hand, in the therapeutic antihypertensive effect, and on the other, in their major side-effect, which is sedation. In fact, it has been recently confirmed that hypotension is mediated by the activation of imidazoline preferring receptors (IPR) within the NRL region, while sedation is attributed to the inhibition of alpha2-adrenergic mechanisms in the locus coeruleus, which is involved in the control of the sleep-waking cycle. The IPRmay constitute on interesting target for new drugs in the treatment of arterial hypertension. Finally, dysfunctions of this modulatory system which could be involved in the pathophysiologyof some forms of the hypertensive disease are under investigation. |
id |
FIOCRUZ-4_40fba5b7847d89a90ffbe38e0cfa59a4 |
---|---|
oai_identifier_str |
oai:scielo:S0074-02761993000200024 |
network_acronym_str |
FIOCRUZ-4 |
network_name_str |
Memórias do Instituto Oswaldo Cruz |
spelling |
The imidazoline receptors and the central regulation of the arterial blood pressure: a minireviewclonidinerilmenidineimidazoline-preferring receptorsnucleus reticularis lateralisarterial hypotensionantihypertensive drugscentral nervous systemRecently, we proposed the hypothesis according to wich the central hypotensive effect of clonidine and related substances could be related to an action upon specific receptors, requiring the imidazoline or imidazoline-like structures, rather than alpha2-adrenoceptors. Since then, direct evidences have been accumulated to confirm the existence of a population of imidazoline specific binding sites in the brainstem of animals and man, more precisely in the Nucleus Reticularis Lateralis (NRL) region of the ventrolateral medulla (VLM), site of the antihypertensive action of clonidine. The purification of the putative endogenous ligand of the imidazoline receptors - named endazoline - is currently being attempted from human brain extracts. This new concept might at last lead to the expected dissociation of the pharmacological mechanisms involved, on the one hand, in the therapeutic antihypertensive effect, and on the other, in their major side-effect, which is sedation. In fact, it has been recently confirmed that hypotension is mediated by the activation of imidazoline preferring receptors (IPR) within the NRL region, while sedation is attributed to the inhibition of alpha2-adrenergic mechanisms in the locus coeruleus, which is involved in the control of the sleep-waking cycle. The IPRmay constitute on interesting target for new drugs in the treatment of arterial hypertension. Finally, dysfunctions of this modulatory system which could be involved in the pathophysiologyof some forms of the hypertensive disease are under investigation.Instituto Oswaldo Cruz, Ministério da Saúde1993-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761993000200024Memórias do Instituto Oswaldo Cruz v.88 n.2 1993reponame:Memórias do Instituto Oswaldo Cruzinstname:Fundação Oswaldo Cruzinstacron:FIOCRUZ10.1590/S0074-02761993000200024info:eu-repo/semantics/openAccessTibiriça,EduardoBricca,GiampieroDontenwill,MoniqueFeldman,JosianeGreney,HuguesBelcourt,AlainStutzmann,JeanneBousquet,Pascaleng2020-04-25T17:47:09Zhttp://www.scielo.br/oai/scielo-oai.php0074-02761678-8060opendoar:null2020-04-26 02:05:40.245Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruztrue |
dc.title.none.fl_str_mv |
The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview |
title |
The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview |
spellingShingle |
The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview Tibiriça,Eduardo clonidine rilmenidine imidazoline-preferring receptors nucleus reticularis lateralis arterial hypotension antihypertensive drugs central nervous system |
title_short |
The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview |
title_full |
The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview |
title_fullStr |
The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview |
title_full_unstemmed |
The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview |
title_sort |
The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview |
author |
Tibiriça,Eduardo |
author_facet |
Tibiriça,Eduardo Bricca,Giampiero Dontenwill,Monique Feldman,Josiane Greney,Hugues Belcourt,Alain Stutzmann,Jeanne Bousquet,Pascal |
author_role |
author |
author2 |
Bricca,Giampiero Dontenwill,Monique Feldman,Josiane Greney,Hugues Belcourt,Alain Stutzmann,Jeanne Bousquet,Pascal |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Tibiriça,Eduardo Bricca,Giampiero Dontenwill,Monique Feldman,Josiane Greney,Hugues Belcourt,Alain Stutzmann,Jeanne Bousquet,Pascal |
dc.subject.por.fl_str_mv |
clonidine rilmenidine imidazoline-preferring receptors nucleus reticularis lateralis arterial hypotension antihypertensive drugs central nervous system |
topic |
clonidine rilmenidine imidazoline-preferring receptors nucleus reticularis lateralis arterial hypotension antihypertensive drugs central nervous system |
dc.description.none.fl_txt_mv |
Recently, we proposed the hypothesis according to wich the central hypotensive effect of clonidine and related substances could be related to an action upon specific receptors, requiring the imidazoline or imidazoline-like structures, rather than alpha2-adrenoceptors. Since then, direct evidences have been accumulated to confirm the existence of a population of imidazoline specific binding sites in the brainstem of animals and man, more precisely in the Nucleus Reticularis Lateralis (NRL) region of the ventrolateral medulla (VLM), site of the antihypertensive action of clonidine. The purification of the putative endogenous ligand of the imidazoline receptors - named endazoline - is currently being attempted from human brain extracts. This new concept might at last lead to the expected dissociation of the pharmacological mechanisms involved, on the one hand, in the therapeutic antihypertensive effect, and on the other, in their major side-effect, which is sedation. In fact, it has been recently confirmed that hypotension is mediated by the activation of imidazoline preferring receptors (IPR) within the NRL region, while sedation is attributed to the inhibition of alpha2-adrenergic mechanisms in the locus coeruleus, which is involved in the control of the sleep-waking cycle. The IPRmay constitute on interesting target for new drugs in the treatment of arterial hypertension. Finally, dysfunctions of this modulatory system which could be involved in the pathophysiologyof some forms of the hypertensive disease are under investigation. |
description |
Recently, we proposed the hypothesis according to wich the central hypotensive effect of clonidine and related substances could be related to an action upon specific receptors, requiring the imidazoline or imidazoline-like structures, rather than alpha2-adrenoceptors. Since then, direct evidences have been accumulated to confirm the existence of a population of imidazoline specific binding sites in the brainstem of animals and man, more precisely in the Nucleus Reticularis Lateralis (NRL) region of the ventrolateral medulla (VLM), site of the antihypertensive action of clonidine. The purification of the putative endogenous ligand of the imidazoline receptors - named endazoline - is currently being attempted from human brain extracts. This new concept might at last lead to the expected dissociation of the pharmacological mechanisms involved, on the one hand, in the therapeutic antihypertensive effect, and on the other, in their major side-effect, which is sedation. In fact, it has been recently confirmed that hypotension is mediated by the activation of imidazoline preferring receptors (IPR) within the NRL region, while sedation is attributed to the inhibition of alpha2-adrenergic mechanisms in the locus coeruleus, which is involved in the control of the sleep-waking cycle. The IPRmay constitute on interesting target for new drugs in the treatment of arterial hypertension. Finally, dysfunctions of this modulatory system which could be involved in the pathophysiologyof some forms of the hypertensive disease are under investigation. |
publishDate |
1993 |
dc.date.none.fl_str_mv |
1993-06-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761993000200024 |
url |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761993000200024 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0074-02761993000200024 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Instituto Oswaldo Cruz, Ministério da Saúde |
publisher.none.fl_str_mv |
Instituto Oswaldo Cruz, Ministério da Saúde |
dc.source.none.fl_str_mv |
Memórias do Instituto Oswaldo Cruz v.88 n.2 1993 reponame:Memórias do Instituto Oswaldo Cruz instname:Fundação Oswaldo Cruz instacron:FIOCRUZ |
reponame_str |
Memórias do Instituto Oswaldo Cruz |
collection |
Memórias do Instituto Oswaldo Cruz |
instname_str |
Fundação Oswaldo Cruz |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
repository.name.fl_str_mv |
Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruz |
repository.mail.fl_str_mv |
|
_version_ |
1669937661456941056 |